TRT Jatenzo denied for missing prior authorization by Aetna?

Aetna's specific coverage criteria for trt jatenzo are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Requires Prior Authorization for Jatenzo — and How to Appeal a Denial

Jatenzo (testosterone undecanoate oral) requires prior authorization (PA) under most Aetna pharmacy benefit plans because testosterone replacement therapies are a category where insurers impose clinical gatekeeping. The PA process is meant to confirm that the prescribed drug matches an FDA-approved indication, that a qualifying diagnosis is documented, and — for oral testosterone specifically — that use of this formulation is appropriate for the patient. A PA denial typically means Aetna found that one or more of its clinical criteria were not sufficiently documented in the initial request, not necessarily that the treatment is inappropriate.

## Federal Appeal Framework

A PA denial is a coverage denial and is fully appealable. Under ACA Section 2719, you have the right to an internal appeal and, if that is denied, to an independent external review. ERISA Section 503 governs employer-sponsored plans and requires a full-and-fair review. You generally have approximately four months from the final internal denial to request external review. If delay poses a serious health risk, request an expedited internal appeal (typically decided within 72 hours) and flag the clinical urgency in writing.

## What to Gather Before You Appeal

• Prescriber's PA request and denial letter. Obtain copies of the original PA submission and the denial explanation. Confirm which specific clinical criteria Aetna states were unmet.
• Diagnosis documentation. Laboratory results and clinical records establishing hypogonadism and its underlying cause, consistent with the FDA-approved indication for Jatenzo.
• Prescriber medical-necessity letter. The treating physician should write a letter that addresses each criterion in Aetna's published clinical policy for testosterone products — obtain that policy directly from Aetna's website before drafting — and explains why Jatenzo's oral route is appropriate for this patient (e.g., patient-specific factors that make injections or topical forms unsuitable or less appropriate).
• Applicable clinical guidelines. Reference the relevant endocrinology society guideline (e.g., Endocrine Society) generically to show that treatment is consistent with accepted clinical practice. Do not cite specific numbers; let the prescriber confirm what the chart shows against the criteria.

## Criteria-Mapping Structure

For each requirement in Aetna's clinical policy, create a row:

| Aetna criterion (from published policy) | Chart evidence meeting it | Source document | |---|---|---| | Confirmed hypogonadism diagnosis | Diagnosis code + lab report | Office visit notes, date | | Underlying medical cause documented | Clinical records | Physician notes | | Appropriate candidate for oral TRT | Prescriber letter | Letter, date |

This table format makes it easy for the reviewer to check off each requirement.

## Timeline and Submission Tips

Submit the appeal in writing, certified mail or through Aetna's secure member portal, and request a written acknowledgment. Note the plan's internal appeal deadline (usually 180 days from denial for standard appeals). If the prescriber can also submit a peer-to-peer review request directly with Aetna's medical director, that parallel track sometimes resolves PA denials faster. Keep the external review option open by noting the clock that starts from the final internal denial.